

Search for a common mechanism of mood stabilizers

Adrian J. Harwood^{a,*}, Galila Agam^b

^aMRC Laboratory for Molecular Cell Biology & Department of Biology, University College London,
Gower St., London, WC1E 6BT, UK

^bPsychiatry Research Unit & Department of Clinical Biochemistry, Faculty of Health Sciences, Ben-Gurion University
of the Negev & Mental Health Center, PO Box 4600, Beersheva 84170, Israel

Abstract

Manic-depression, or bipolar affective disorder, is a prevalent mental disorder with a global impact. Mood stabilizers have acute and long-term effects and at a minimum are prophylactic for manic or depressive poles without detriment to the other. Lithium has significant effects on mania and depression, but may be augmented or substituted by some antiepileptic drugs. The biochemical basis for mood stabilizer therapies or the molecular origins of bipolar disorder is unknown. One approach to this problem is to seek a common target of all mood stabilizers. Lithium directly inhibits two evolutionarily conserved signal transduction pathways. It both suppresses inositol signaling through depletion of intracellular inositol and inhibits glycogen synthase kinase-3 (GSK-3), a multifunctional protein kinase. A number of GSK-3 substrates are involved in neuronal function and organization, and therefore present plausible targets for therapy. Valproic acid (VPA) is an antiepileptic drug with mood-stabilizing properties. It may indirectly reduce GSK-3 activity, and can up-regulate gene expression through inhibition of histone deacetylase. These effects, however, are not conserved between different cell types. VPA also inhibits inositol signaling through an inositol-depletion mechanism. There is no evidence for GSK-3 inhibition by carbamazepine, a second antiepileptic mood stabilizer. In contrast, this drug alters neuronal morphology through an inositol-depletion mechanism as seen with lithium and VPA. Studies on the enzyme prolyl oligopeptidase and the sodium *myo*-inositol transporter support an inositol-depletion mechanism for mood stabilizer action. Despite these intriguing observations, it remains unclear how changes in inositol signaling underlie the origins of bipolar disorder.

© 2003 Elsevier Science Inc. All rights reserved.

Keywords: Lithium; Valproate; Carbamazepine; GSK-3; Inositol phosphate signaling; Manic-depression

1. Introduction

Carl Lange discovered lithium as a treatment for manic-depression in the 1880s [1]. Its initial use declined for lack of a credible therapeutic mechanism—it was originally linked to the idea that manic-depression, now known as bipolar affective disorder, and a number of other medical

conditions arose through a buildup of uric acid [2]. Lithium was re-discovered in 1949 by John Cade [3], and since then has been used as an effective treatment for both acute and long-term phases of bipolar affective disorder. It is estimated that 1 in 1000 people may be taking lithium in the United States. Although clearly beneficial (the suicide rate of untreated patients runs at higher than 15%), lithium treatment is not without problems. These include potential serious side-effects and individuals who fail to respond [4]. Although perhaps not as effective as lithium on both depression and mania, some antiepileptic drugs have also been found to have mood-stabilizing properties, but again these are not without complications [5,6]. Despite an intense research effort from academic and clinical institutions and the pharmaceutical industry, the development of better mood stabilizers has been slow. Probably, the greatest barrier to progress is still our lack of a molecular understanding of the mechanisms that underlie the origin and treatment of this disorder.

* Corresponding author. Tel.: +44-207679-7257;
fax: +44-207679-7805.

E-mail addresses: a.harwood@ucl.ac.uk (A.J. Harwood),
agamg@netvision.net.il, galila@bgumail.bgu.ac.il (G. Agam).

Abbreviations: DRG, dorsal root ganglia; GSK-3, glycogen synthase kinase-3; IMPase, inositol monophosphatase; InsP, inositol phosphate; Ins(1,4,5)P₃, inositol 1,4,5-trisphosphate; IPP, inositol polyphosphate 1-phosphatase; PAP, 3'-phosphoadenosine 5'-phosphate; PAPS, 3'-phosphoadenosine 5'-phosphosulphate; PI3 kinase, phosphatidylinositol 3-kinase; PI(4,5)P₂, phosphatidylinositol (4,5) bisphosphate; PLC, phospholipase C; PO, prolyl oligopeptidase; RnPIP, *Rattus norvegicus* 3'-phosphoadenosine 5'-phosphate and inositol 1,4-bisphosphate phosphatase; and VPA, valproic acid.

2. Lithium

In addition to its therapeutic uses, embryologists have long known lithium as a teratogen: a drug that affects patterning and proportion of cell types in the developing embryo. For example, in sea urchins, lithium causes vegetalization of the animal blastomeres [7] and in vertebrates, such as *Xenopus* and zebrafish, it causes expansion of the dorsal mesoderm and duplication of the dorsal axis [8,9]. These effects are not restricted to animals, as lithium treatment of *Dictyostelium*, a non-metazoan eukaryote, leads to mis-specification of spore and basal disc cell fate [10,11]. Despite the assumed clinical risk during pregnancy, there are surprisingly few reports of teratogenic effects of lithium on human development, although some reports have suggested an increased risk of heart defects [12].

A number of signal transduction pathways are affected by lithium treatment, but many of the reported effects appear to be indirect [13]. Currently, only two protein families have been demonstrated as direct cellular targets of lithium and are affected at close to therapeutic concentrations. IMPase is the best known member of a super-family of structurally related phosphomonoesterases [14]. Biochemical and structural studies of a number of family members, including IMPase, IPP, fructose 1,6-bisphosphatase, and the rat PAP phosphatase (RnPIP), have revealed a magnesium ion binding site within the active site of the enzyme that is targeted by lithium [15–17]. This magnesium ion is not required for direct hydrolysis of the phosphodiester bond, but is required for binding the cleaved product and phosphate. Lithium prevents product release and traps products in the active site; this results in an uncompetitive mode of inhibition [18].

Some lithium-sensitive phosphomonoesterases, including RnPIP and the *Saccharomyces cerevisiae* protein Hal2, dephosphorylate both PAP and inositol 1,4-bisphosphate, with in many cases the PAP phosphatase activity being the dominant enzyme activity [19]. PAP phosphatase catalyses the hydrolysis of PAP to form AMP [20]. Lithium inhibition, therefore, may lead to increased PAP, which is a potent inhibitor of enzymes that utilize PAPS, such as the sulphotransferases. Loss of PAP phosphatase genes in yeasts causes sulfur and methionine auxotrophy, and inhibits RNA processing [21]. It is not yet clear whether blocking PAP phosphatase contributes to the overall therapeutic effects of lithium treatment.

Lithium also inhibits the GSK-3 family of serine/threonine protein kinases [22]. These are a highly conserved family of kinases that have been identified in all eukaryotic groups examined to date. In vertebrates, GSK-3 is found as two isoforms: GSK-3 α and GSK-3 β plus a splice variant of GSK-3 β [23,24]. In other organisms, the number of genes varies from one in *Dictyostelium* to four in *S. cerevisiae*, and even more in plants [25]. Lithium has been demonstrated to inhibit GSK-3 both *in vitro* and *in vivo* [22]. Enzyme kinetic experiments suggest that this is also through competition for magnesium ion binding [26,27].

In contrast to phosphomonoesterases, lithium is a non-competitive inhibitor with respect to its protein substrates. The fact that lithium inhibits both of these enzyme groups through an interaction with magnesium suggests that this may be a general mechanism of lithium action. Lithium could, therefore, potentially target all magnesium binding proteins. However, those with low-affinity magnesium sites, of which only phosphomonoesterases and GSK-3 are known, may be sensitive to the concentrations used in both therapeutic and experimental conditions. In this commentary, we will further consider the consequences of IMPase and GSK-3 inhibition.

3. Lithium and InsP signaling

Over 20 years ago, it was shown that lithium perturbs InsP metabolism by inhibition of IMPase and IPP [28]. Inositol plays a role in signal transduction in two ways. The soluble InsPs bind to receptors in the cytoplasm. The most well-known example is Ins(1,4,5)P₃, which binds to a receptor on the surface of the endoplasmic reticulum to release calcium [29]. This then elicits a range of cell responses, including activation of protein kinases such as PKC. Other InsP species, particularly Ins(1,3,4,5)P₄ and InsP₆, have also been ascribed signal functions [30]. Inositol is also incorporated into phosphatidylinositol phosphates, present in the plasma membrane. Both PI(4,5)P₂ and a variety of phosphatidylinositides phosphorylated at the 3' carbon form protein binding sites within the membrane and lead to protein translocation from the cytoplasm [31].

PI(4,5)P₂ is hydrolyzed by PLC to generate Ins(1,4,5)P₃ and diacylglycerol (DAG). PLC activity is directly regulated through ligand-stimulated receptors and can lead to acute changes in Ins(1,4,5)P₃ concentrations [32]. Ins(1,4,5)P₃ is then degraded by a 5'-phosphatase and IPP to form inositol monophosphate (InsP₁). The final phosphate is removed by IMPase to release free inositol, which then can be reincorporated into membrane PIPs. In addition to the recycling of inositol from InsPs, IMPase is also required for *de novo* synthesis of inositol from glucose-6-phosphate, which is isomerized by inositol-1-phosphate synthase to InsP₁ [33]. On the basis of these observations, Berridge *et al.* [34] proposed the inositol-depletion hypothesis, in which inhibition of IMPase by lithium reduces the pool of free inositol and therefore suppresses inositol-based signaling (Fig. 1). The uncompetitive inhibition of IMPase by lithium—where inhibition is dependent upon both the inhibitor and the substrate—means that lithium may preferentially act on those cells generating the most InsP₁.

There is little doubt that lithium can inhibit IMPase in brain slices [35,36], but the overall effect on Ins(1,4,5)P₃ varies between species; in some cases Ins(1,4,5)P₃ concentrations rise [37,38]. Lithium treatment, however, increases neurotransmitter release and may therefore increase Ins(1,4,5)P₃ synthesis through indirect effects




Fig. 1. An extended view of inositol-based signal transduction. Inositol is rate limiting for the synthesis of the phosphatidylinositol bisphosphate, PI(4,5)P₂. This membrane lipid is either further phosphorylated to PI(3,4,5)P₃ by PI3 kinase, or hydrolyzed to diacylglycerol and soluble Ins(1,4,5)P₃ by ligand-stimulated PLC enzymes. Ins(1,4,5)P₃ induces Ca²⁺ release from intracellular stores. The cellular Ins(1,4,5)P₃ concentration is reduced by phosphorylation to create higher order inositol phosphates or dephosphorylation to inositol. This latter pathway recycles inositol into the signal pathway. The enzymes inositol polyphosphate 1-phosphatase (IPP) and inositol monophosphatase (IMPase), which catalyse the final dephosphorylation steps, are lithium sensitive. Inositol is synthesized by isomerization of glucose-6-phosphate by the enzyme inositol synthase (Ino-1). As *de novo* synthesis involves an IP₁ intermediate, it is also blocked by lithium treatment. Environmental inositol is taken into the cell via a high-affinity sodium *myo*-inositol transporter (SMIT). Finally, inositol can be released from high order inositol phosphates. Multiple inositol polyphosphate phosphatase (MInsPP) dephosphorylates InsP₆ to Ins(1,4,5)P₃ and is regulated by prolyl oligopeptidase (PO).

[39]. Changes in whole brain biochemistry may be uninformative, and mood disorders could arise through region- or cell-specific changes in brain biochemistry. Indeed, brain scans indicate that changes in the metabolic activity correlated to mood disorders and treatment are restricted to specific brain regions [40,41]. At the subcellular level, lithium induces structural changes in the termini of peripheral neurons. In *Drosophila*, either lithium treatment or loss of IPP leads to ultrastructural changes in the neuromuscular junction and aberrant firing [42]. Lithium treatment of explants of DRG leads to increased spreading of the growth cone present at the axon terminus [43]. This effect is reversed by the addition of *myo*-inositol, compatible with an inositol-depletion mechanism.

Using reversal by inositol as a criterion, a number of brain physiological and behavioral effects of lithium have been ascribed to changes in InsP signaling. Lithium-induced suppression of rearing is well described in rats, and has been shown to be suppressed by intracerebroventricular injection of inositol [44,45]. A more defined effect is seen with limbic seizures induced by an injection of lithium followed by pilocarpine [46]. Again this effect can be suppressed by inositol. A number of observations, however, appear inconsistent with the inositol-depletion hypothesis. First, the reversal of lithium depletion would be expected to be specific for *myo*-inositol, which is the only stereoisomer utilized in the production of phosphatidylinositol. Whereas *L*-chiro-inositol fails to reverse the effects of lithium, in some cases *epi*-inositol does not [47,48]. Second, studies indicate that high daily intake

of inositol, in the range of 6–12 g, may have positive effects on patients with depression [49,50]. These observations indicate a more complex cellular interaction with inositol (see Section 8). They may also be indicative of other mechanisms of lithium action.

4. Lithium and GSK-3

4.1. GSK-3 and Wnt signaling

GSK-3 was first identified as an enzymatic activity that phosphorylates and inactivates glycogen synthase [51]. This enzyme is a key target of the insulin response, which acts through GSK-3 inhibition. Consistent with its inhibition of GSK-3, lithium restores glycogen synthesis to hepatocytes from diabetic rats [52]. GSK-3, however, has many targets and functions within the cell [53] (Fig. 2). For example, GSK-3 phosphorylates a number of important transcription factors and cytoskeletal proteins. Among its targets is the protein β -catenin, which serves both functions, being a component of adherens junctions and a regulator of the LEF-1/TCF-3 family of transcription factors. GSK-3 phosphorylation of β -catenin leads to its degradation and hence blocks its function. The GSK-3 interaction with β -catenin appears to be insulated from other GSK-3-mediated events through their mutual binding to the protein Axin [54]. Function of the GSK-3–Axin– β -catenin complex is negatively regulated by the extracellular ligand Wnt, which when bound to its co-receptors Frizzled and LRP5 or 6 blocks




Fig. 2. Multiple roles for GSK-3. GSK-3 lies downstream of a number of apparently independent signal transduction pathways. In a complex with Axin, GSK-3 phosphorylates β -catenin, causing its degradation and preventing expression of genes, such as *c-myc* and cyclin D1. Cell stimulation by Wnt inhibits the action of GSK-3 on β -catenin, via a process that requires Dishevelled (Dsh or dvl). Wnt and dvl also regulate GSK-3 phosphorylation of MAP1B, in a β -catenin-independent manner (the role of Axin in this pathway is unknown). MAP1B and tau are both targets of GSK-3 and regulate microtubule behavior. In *Drosophila*, the cleavage of the transcription factor Cubitus interruptus (Ci) is regulated by GSK-3 phosphorylation. Ci cleavage is also regulated by Hedgehog (Hh) stimulation, although the interaction of this signal with GSK-3 has not been investigated, and leads to regulation of gene expression, including the cyclin D and cyclin E genes. Insulin, growth factors, and neurotrophic factors may activate PI3 kinase and inhibit GSK-3 through the action of PKB. This pathway regulates a number of cellular processes, such as intermediate metabolism. It has also been implicated in regulating apoptosis (cell death).

GSK-3 phosphorylation of β -catenin via a mechanism that requires the protein Dishevelled, known as Dsh or dvl, in mice [55,56]. Overexpression of β -catenin, Wnt, or Dsh in fertilized *Xenopus* oocytes leads to axis duplication as also seen following lithium injection [57].

In 1995, it was shown that injection of a dominant-negative GSK-3 causes axis duplication in *Xenopus* [58]. At the same time, the effect of GSK-3 gene disruption in the cellular slime mold *Dictyostelium discoideum* was published [25]. Disruption of the *Dictyostelium* GSK-3 homologue, *gskA*, removes all GSK-3 activity from the cells and leads to a specific pattern formation defect during its multicellular development. The same pattern defect had been reported in an earlier paper when *Dictyostelium* cells were developed in the presence of LiCl [10]. These observations suggested that lithium could exert its effects through the inhibition of GSK-3. Klein and Melton [22] showed that indeed lithium does inhibit GSK-3 activity. This inhibitory effect was also reported by Stambolic *et al.* [59], who further demonstrated that treatment of intact cells with lithium led to reduced GSK-3 activity *in vivo*, as assessed by stabilization of β -catenin and the decrease in the phosphorylation of another GSK-3 substrate, tau.

4.2. GSK-3 and the CNS

There are strong reasons to argue for a role of GSK-3 in the development and function of the CNS. Wnt protein signals are abundant during the development of the CNS,

and persist into adulthood [60]. Wnt7A is expressed in the mouse cerebellum during post-natal development [61]. Wnt7A, dvl, and lithium all induce large-scale changes in the axonal cytoskeleton (Fig. 2) and redistribution of the presynaptic protein synapsin I when applied to cells isolated from this region [61–63]. Changes are particularly apparent in the microtubule cytoskeleton [64]. In growth cones of developing neurons, Wnt and lithium treatment causes changes in the distribution of stable microtubules. In addition, branching increases along the axon length [64]. Therefore, inhibiting GSK-3 could potentially lead to an increased synapse number and size, although this has yet to be demonstrated. These effects do not appear to require β -catenin, but are seen in a double-knockout mouse, which lacks both of the microtubule binding proteins MAP1B and tau, both substrates of GSK-3 [65].

Although pointing to important roles for GSK-3 in the development of both fine and gross structure within the brain, none points to a direct target for the therapeutic action of lithium. The discovery of neurogenesis and apoptosis within the adult brain presents a new potential role for GSK-3. In mammals, adult neurogenesis (the production of new neurons) occurs in certain layers of the hippocampus, where about 3% of the cells undergo division [66,67]. In rodents and primates, both proliferation and survival of cells in this region are increased by exercise, environmental enrichment, and learning, whereas stress reduces neurogenesis [68–72]. Neuroimaging and examination of postmortem brains show localized changes in volume and cell number within the

hippocampus and frontal cortex of patients with bipolar disorder [41]. Lithium treatment of mice increased the number of dividing cells and those expressing the anti-apoptotic gene *Bcl-2* within the dentate gyrus of the hippocampus [73].

Cell number is the net balance between cell division and cell death, and both could potentially be regulated by GSK-3. Deletion of the GSK-3 sites of β -catenin, inactivating mutations of Axin, and failure to degrade β -catenin protein have been associated with a wide range of cancers [74]. The molecular basis of these cancers is found in the up-regulation of gene expression. Although not all experiments agree, common genes up-regulated include *c-myc* and cyclin D1 [75–77]. Regulation of β -catenin also involves the presenilin protein PS-1 [78,79]. Mutations of PS-1 are associated with familial Alzheimer's disease (AD), indicating a role in the brain. Loss of PS-1 in mice leads to increased β -catenin protein and cell division [80]. GSK-3 has also been shown to be a component of the Hh signaling pathway, which is active during brain development (Fig. 2). In *Drosophila*, GSK-3 acts on the transcription factor Cubitus interruptus (Ci) [81,82]. Additionally, Hh signaling lead to changes in expression of the cyclin D and cyclin E genes (Fig. 2) [83,84]. Finally, GSK-3 phosphorylation also regulates the export of cyclin D1 from the nucleus during S-phase [85]. As a consequence of these interactions, there are many potential routes by which GSK-3 could regulate cell division in the adult brain; however, none of these has actually been demonstrated.

4.3. GSK-3 and cell death

GSK-3 may act as a modulator of apoptosis. Treatment of rat hippocampal neurons with the β -amyloid (A β) peptide, which builds up in patients with AD, both increases GSK-3 β expression and induces apoptosis [86,87]. The apoptotic effect is blocked by antisense oligonucleotides directed at GSK-3. Wnt stimulation also protects against apoptosis, although this may be due to indirect induction of IGF proteins [88]. Insulin, IGFs, NGF, and BDNF can all inhibit GSK-3 through activation of PI3 kinase [53] (Fig. 2). Inhibition of PI3 kinase, by use of chemical inhibitors or serum withdrawal, leads to increased GSK-3 activity, and this correlates with apoptosis [89–91]. In addition, full GSK-3 activity requires phosphorylation at an internal tyrosine (Tyr²¹⁶) [54]. Interestingly, it has been shown that several apoptotic stimuli induce an increase in Tyr²¹⁶ phosphorylation and increase GSK-3 activity [92]. Consistent with these observations, overexpression of GSK-3 also correlates with neuronal degeneration [93]. Moderate increases in GSK-3 activity in human neuroblastoma SH-SY5Y cells did not increase the basal rate of apoptosis or caspase-3, which sits within the apoptotic signal transduction pathway, but they are associated with increased sensitivity to apoptotic stimuli [94,95]. These effects are blocked by expression of the

anti-apoptotic protein Bcl-2 and expression of a dominant-negative p53 mutant [96,97]. Consistent with a role of GSK-3, many of these effects can be reduced by lithium treatment [98].

5. VPA

We are therefore presented with two plausible lithium targets active in neural systems; both can modulate neuronal structure, in addition to their roles during animal development. It is therefore possible that inhibition of either target could explain the therapeutic properties of lithium on bipolar mood disorder. A number of researchers are beginning to examine the molecular actions of other mood-stabilizing drugs in an attempt to resolve this issue.

VPA is now the most widely prescribed antiepileptic drug and is being used increasingly in the treatment of bipolar disorder, especially in the United States. As with other anticonvulsants, VPA inhibits sodium, potassium, and calcium channel function, although its direct *in vivo* target has not been identified definitively [99]. In common with lithium, it has been shown to reduce expression of the protein kinase C isoforms PKC α and PKC ϵ , activate MAP kinase and its downstream targets, increase expression of Bcl-2, and activate AP-1-dependent transcription [100–103]. Unlike lithium, VPA appears to be a potent human teratogen, increasing the risk of a number of congenital anomalies, including 1–3% increased risk for spina bifida, congenital heart defects, and anomalies of limb and digit development. VPA administration to mice leads to embryonic neural tube defects [104].

Initially, VPA was reported to directly inhibit GSK-3 activity; however, this has not been substantiated in a number of further experiments [105–107]. One report suggests that VPA treatment could lead to an indirect change in GSK-3 activity, but this is not seen in all cases [43,107]. In *Dictyostelium*, VPA treatment does not phenocopy the *gskA* loss of function mutant, indicating that it does not target GSK-3 [43]. VPA, however, has been demonstrated to mimic the effect of lithium on the Wnt signaling pathway by increasing the expression of β -catenin [106] This occurs through direct inhibition of the transcriptional repressor histone deacetylase (HDAC), and increased β -catenin expression is also seen after treatment with the chemically unrelated HDAC inhibitor trichostatin A (TSA). This mechanism may explain some of the effects of VPA on gene expression and animal development. The effects of VPA inhibition of HDAC appear to be cell context specific and vary between specific cases. For example, VPA or TSA treatment of DRG cells for 48 hr failed to increase β -catenin expression and had the opposite effect to lithium on axonal branching [43]. The non-teratogenic VPA analogue valpromide (VPM) does not inhibit HDAC, but has been reported to possess mood-stabilizing properties [106–108]. It has a “synchro-

nizing” effect on the reduced heart rate circadian rhythm seen in patients with unipolar and bipolar disorders [109]. This argues against HDAC as a therapeutic target in the treatment of mood disorders.

The effect of VPA on inositol signaling has been investigated in mammals and a number of microorganisms. VPA decreases *myo*-inositol concentrations in yeast, in *Dictyostelium*, and in the human and rat brain [43,110–112]. The intracellular inositol concentration feeds back to regulate expression of the inositol-1-phosphate synthase enzyme and expression of the gene encoding this enzyme, *ino-1*, can be used to indirectly monitor the intracellular inositol concentration. This has been done for both the yeast *S. cerevisiae* and *Dictyostelium* [43,110]. In both cases, lithium and VPA increase *ino-1* expression, and this effect is reversed by addition of exogenous *myo*-inositol. In *Dictyostelium*, both lithium and VPA reduce total Ins(1,4,5)P₃ concentrations and impair cell aggregation. Here, combining lithium and VPA at subthreshold concentrations leads to an enhanced effect, suggesting that each drug works within the same signal transduction pathway, but on different components. In rat DRG cells, lithium and VPA both have a common effect on growth cone spreading. This effect is again reversed by the addition of *myo*-inositol, indicative of an inositol-depletion mechanism [43]. These observations are consistent with a common effect of VPA on inositol signaling.

6. Carbamazepine

Carbamazepine is a second anticonvulsant found to be beneficial in the treatment of bipolar disorder and, as for VPA, may be advantageous over lithium in non-classical bipolar conditions such as mixed mood states and rapid cycling conditions [113]. Again, it appears to have teratogenic effects and, like VPA, has been associated with an increased risk of neural tube defects; however, many of its targets appear to be distinct from lithium and VPA [104]. Few studies have been made on its biochemical and cell biological effects. Carbamazepine has no direct or indirect effect on GSK-3 activity¹ and, in contrast to lithium and VPA, has no effect on β -catenin protein stability or expression [43]. Its effects have been examined on caspase-3 activity in a GSK-3 transfected neuroblastoma SH-SY5Y cell line [114]. Here, induction of caspase-3 activity by staurosporine and heat shock is reduced in cells treated with lithium and VPA but not carbamazepine. It is also interesting to note a report suggesting that the recently discovered anticonvulsant mood stabilizer lamotrigine behaves like lithium and VPA in these cells [114]. Although apparently this may suggest a common pathway for three out of four drugs, it is important to consider the multiple pathways, including feedback loops, which regulate caspase activity.

The common outcome of decreased caspase-3 activity may be sensitive to inhibition of these multiple, but distinct pathways.

Two reports favor a common interaction of lithium, VPA, and carbamazepine in the regulation of InsP signaling. First, it has been seen that carbamazepine can reduce the elevated free intracellular calcium ion concentrations found in blood platelets and lymphocytes of patients with bipolar disorder [115]. Second, the effect of carbamazepine has been examined on growth cone spreading of rat DRG cells [43]. Here, as seen with lithium and VPA, carbamazepine increases the spreading and reduces the contraction of growth cones. As seen with lithium and VPA, addition of *myo*-inositol to the medium reverses the effect and returns growth cone spread areas to that seen in untreated controls.

7. PO and lithium resistance

Dictyostelium is a haploid organism and can be manipulated using the full range of molecular genetic tools [116]. Insertional mutagenesis has been used to raise a collection of mutants with reduced sensitivity to lithium [117]. These mutants appear to fall into two classes: one affecting the GSK-3-mediated signal transduction pathway, the other reversing the effect of lithium on InsP signaling. The mutant *lisA* can aggregate in the presence of high concentrations of lithium (>10 mM) and has an elevated Ins(1,4,5)P₃ concentration [117]. The increase in Ins(1,4,5)P₃ arises through up-regulation of the activity of the enzyme multiple inositol polyphosphate phosphatase (MInsPP). This enzyme is present in *Dictyostelium* and mammals and generates Ins(1,4,5)P₃ from InsP₆ [118]. InsP₆ is very abundant in the cell and may act as a cellular store of inositol and phosphate. Increasing MInsPP activity could therefore lead to lithium resistance by increasing the cellular pool of inositol (Fig. 1).

The gene disrupted in the *lisA* mutant has been cloned and encodes a PO. This enzyme has been characterized by its ability to cleave peptides of less than 3 kDa at a proline residue; such peptides include peptide hormones and neuropeptides [119]. It is unclear, however, whether these biopeptides are physiologically relevant substrates as PO activity appears to be cytosolic, with only small extracellular amounts. However, PO activity is important for brain function as its inhibitors enhance memory [120–123]; lithium has the opposite effect on memory [124]. Both lithium resistance and elevated Ins(1,4,5)P₃ can be induced in wild-type *Dictyostelium* cells by treatment with PO inhibitors [117]. The inverse relationship between PO activity and Ins(1,4,5)P₃ concentration is also present in the astrogloma cell line U343 [125]. Changes of PO activity have been associated previously with mood disorders as well as a small number of other mental illnesses. Maes *et al.* [126,127] showed that patients with unipolar

¹Ryves WJ and Harwood AJ, unpublished data.

mood disorder have lowered PO activity and those with bipolar mood disorder have higher PO activity.

Although isolated for lithium resistance, *lisA* has been tested for its effect on sensitivity to VPA. Consistent with an effect on InsP signaling, the *lisA* mutant is cross-resistant to VPA treatment. An effect on GSK-3 can be eliminated, and a double mutant combining *gskA* and PO mutations shows no genetic interaction. To test whether these genetic and biochemical observations hold true for the mammalian neurons, rat DRG cells treated with lithium, VPA, or carbamazepine were also treated with PO inhibitors [43]. In all three cases, PO inhibition reversed the effect of drug treatment. These observations again argue for a common effect of these three mood-stabilizing drugs on InsP signaling. The interaction between the InsP signaling pathway and PO raises the intriguing possibility that changes in InsP metabolism may, in part, underlie the cellular basis for mood disorders.

Consistent with a hypothesis that high PO activity associated with bipolar disorder leads to decreased InsP metabolism—the opposite effect to PO inhibition—inositol has indeed been found to be lower in bipolar patients. Shimon *et al.* [128] and Davanzo *et al.* [129] report reduced postmortem frontal cortex inositol levels in bipolar patients [130]. Inositol levels in lymphocytes derived from cell lines from bipolar patients were also significantly lower than those of cell lines from controls [131]. Banks *et al.* [132] reported a reduced inositol incorporation into membrane phosphoinositides of lymphoblastoid cell lines derived from bipolar patients, and reduced levels of phosphatidylinositol bisphosphate are seen in platelet membranes from bipolar patients [133]. The decreased inositol concentration is accompanied by an approximately 50% reduction of IMPase activity in lymphocytes from cell lines derived from bipolar patients [134,135] and a 66% decrease in mRNA of the IMPase gene, *IMPA1*, in fresh lymphocytes derived from drug-free bipolar patients [136]. These results, however, present a paradox as lithium and the other mood stabilizers would be expected to further lower inositol levels and hence be detrimental to treatment. In contrast, lithium, VPA, and carbamazepine would be expected to be beneficial in situations where PO activity is reduced, such as in patients with unipolar depression.

8. Inositol uptake and mood stabilizers

A further twist to the inositol-depletion hypothesis is that lithium, VPA, and carbamazepine inhibit inositol uptake. Some cells such as isolated oocytes during embryonic development or developing *Dictyostelium* may experience low or no environmental inositol. However, for most cells, inositol is readily available—we ingest 1 g of inositol per day in our diet. The cerebrospinal fluid inositol concentration is between 400 and 600 μM , 10- to 20-fold higher than the K_m of the sodium *myo*-inositol transporter (SMIT) [137] (Fig. 1). Given these figures, cells within the brain ought to

be protected from inositol depletion. Among brain cells, the astrocytes express particularly high levels of SMIT. Lithium, VPA, and carbamazepine treatment of astrocyte cultures reduces both SMIT activity and mRNA concentrations [138]. This effect accumulates slowly with a time course remarkably close to the therapeutic time course. It is also dependent upon *myo*-inositol concentration, and curiously at low inositol concentrations (25 μM) mood stabilizers increase inositol uptake [139]. The mechanism by which these drugs affect SMIT is unclear. Effects on SMIT activity could also explain the unexpected result that inositol itself may act as a mood stabilizer as high external concentrations of inositol may down-regulate inositol uptake [140,141].

9. Conclusions

Lithium is an efficacious and effective drug used to treat bipolar disorder, and is also beneficial against other forms of mood disorders. It is recognized that it has a number of limitations. At the cell and molecular level, it is clear from this discussion that it has a wide range of protein targets and impinges on a broad spectrum of cell processes, including metabolism, gene expression, cell division, and death. It seems inconceivable that all of these processes are therapeutic targets of lithium in the treatment of mood disorders. Rather, it is more likely that many contribute to side-effects and, in fact, limit its use. There is, therefore, a strong case for the development of new mood-stabilizing drugs. The rationale for the development of new drugs relies on a good knowledge of potential molecular targets and, hence, a clear understanding of cell and molecular mechanisms involved in the origins and progression of the illness. This is currently lacking for all mood disorders. It is hoped, however, that investigating the mechanisms of action of the current treatments will illuminate the underlying molecular mechanisms.

The logic in seeking common effects of lithium and the other mood-stabilizing drugs is that they represent the relevant pathway targeted in mood disorders, whereas unrelated effects would be specific for a single drug or a subset of drugs. Considering the conservation of signal transduction pathways between different cellular processes and throughout evolution, this approach has the advantage that initial studies can be carried out in cell culture and even with genetically tractable microorganisms such as yeast and *Dictyostelium*, before progressing to animal behavior and clinical studies. A disadvantage is that given the complexity of bipolar disorder there may not actually be a single molecular target. Treatment may, in fact, result from the balance of inhibition of a number of pathways. Indeed, while some of the patients benefit from the combination of lithium and VPA or carbamazepine, other respond well to either lithium or VPA alone.

Considering all of the evidence, it is clear that at present no definitive conclusion can be drawn as to the identity of a

single common target in the treatment of mood disorders. Recent observations on the pharmacology of VPA and carbamazepine, the properties of PO mutants, and effects on SMIT activity give new perspectives and strengthen the long-standing proposition that lithium treatment acts through an inositol-depletion mechanism. There remain difficulties, however, in relating changes in inositol metabolism to clinical observations of bipolar patients. On the other hand, recent observations on changes in brain structure could relate to inappropriate GSK-3 activity, although at present there is no definitive evidence that this is the case for lithium or the other common mood stabilizers. What is certain is that the search for a common target will continue, and further studies examining other drugs with mood-stabilizing properties will either strengthen the case for InsP signaling, swing the argument back in favor of GSK-3, or reveal a new, unexpected alternative common target.

References

- [1] Healy D. The creation of psychopharmacology. Cambridge, MA: Harvard University Press; 2002.
- [2] Agranoff BW, Fisher SK. Inositol, lithium, and the brain. *Psychopharmacol Bull* 2001;35:5–18.
- [3] Mitchell PB. On the 50th anniversary of John Cade's discovery of the anti-manic effect of lithium. *Aust NZ J Psychiatry* 1999;33:623–8.
- [4] Lenox RH, McNamara RK, Papke RL, Manji HK. Neurobiology of lithium: an update. *J Clin Psychiatry* 1998;59:37–47.
- [5] Keck Jr PE, McElroy SL. Carbamazepine and valproate in the maintenance treatment of bipolar disorder. *J Clin Psychiatry* 2002;63(Suppl 10):13–7.
- [6] Mitchell PB, Malhi GS. The expanding pharmacopoeia for bipolar disorder. *Annu Rev Med* 2002;53:173–88.
- [7] Livingston BT, Wilt FH. Lithium evokes expression of vegetal-specific molecules in the animal blastomeres of sea urchin embryos. *Proc Natl Acad Sci USA* 1989;86:3669–73.
- [8] Kao KR, Elinson RP. Dorsalization of mesoderm induction by lithium. *Dev Biol* 1989;132:81–90.
- [9] Driever W. Axis formation in zebrafish. *Curr Opin Genet Dev* 1995;5:610–8.
- [10] Maeda Y. Influence of ionic conditions on cell differentiation and morphogenesis of the cellular slime molds. *Dev Growth Differ* 1970;12:217–27.
- [11] Peters DJM, Snaar-Jagalska BE, Van Haastert PJM, Schaap P. Lithium, an inhibitor of cAMP-induced inositol 1,4,5-trisphosphate accumulation in *Dictyostelium discoideum*, inhibits activation of guanine-nucleotide-binding regulatory proteins, reduces activation of adenylate cyclase, but potentiates activation of guanylyl cyclase by cAMP. *Eur J Biochem* 1992;209:299–304.
- [12] Jacobson SJ, Jones K, Johnson K, Ceolin L, Kaur P, Sahn D, Donnenfeld AE, Rieder M, Santelli R, Smythe J, Pastuszak A, Einarson T, Koren G. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. *Lancet* 1992;339:530–3.
- [13] Phiel CJ, Klein PS. Molecular targets of lithium action. *Annu Rev Pharmacol Toxicol* 2001;41:789–813.
- [14] Atack JR, Broughton HB, Pollack SJ. Inositol monophosphatase—a putative target for Li⁺ in the treatment of bipolar disorder. *Trends Neurosci* 1995;18:343–9.
- [15] Bone R, Springer JP, Atack JR. Structure of inositol monophosphatase, the putative target of lithium therapy. *Proc Natl Acad Sci USA* 1992;89:10031–5.
- [16] York JD, Ponder JW, Chen ZW, Mathews FS, Majerus PW. Crystal structure of inositol polyphosphate 1-phosphatase at 2.3-Å resolution. *Biochemistry* 1994;33:13164–71.
- [17] Patel S, Yenush L, Rodriguez PL, Serrano R, Blundell TL. Crystal structure of an enzyme displaying both inositol-polyphosphate-1-phosphatase and 3'-phosphoadenosine-5'-phosphate phosphatase activities: a novel target of lithium therapy. *J Mol Biol* 2002;315:677–85.
- [18] Atack JR, Broughton HB, Pollack SJ. Structure and mechanism of inositol monophosphatase. *FEBS Lett* 1995;361:1–7.
- [19] López-Coronado JM, Bellés JM, Lesage F, Serrano R, Rodríguez PL. A novel mammalian lithium-sensitive enzyme with a dual enzymatic activity, 3'-phosphoadenosine 5'-phosphate phosphatase and inositol-polyphosphate 1-phosphatase. *J Biol Chem* 1999;274:16034–9.
- [20] Murguía JR, Bellés JM, Serrano R. A salt-sensitive 3'(2'),5'-bisphosphate nucleotidase involved in sulfate activation. *Science* 1995; 267:232–4.
- [21] Miyamoto R, Sugiura R, Kamitani S, Yada T, Lu Y, Sio SO, Asakura M, Matsuhisa A, Shuntoh H, Kuno T. Tol1, a fission yeast phosphomonoesterase, is an in vivo target of lithium, and its deletion leads to sulfite auxotrophy. *J Bacteriol* 2000;182:3619–25.
- [22] Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. *Proc Natl Acad Sci USA* 1996;93:8455–9.
- [23] Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. *EMBO J* 1990;9:2431–8.
- [24] Murai H, Okazaki M, Kikuchi A. Tyrosine dephosphorylation of glycogen synthase kinase-3 is involved in its extracellular signal-dependent inactivation. *FEBS Lett* 1996;392:153–60.
- [25] Harwood AJ, Plyte SE, Woodgett J, Strutt H, Kay RR. Glycogen synthase kinase 3 regulates cell fate in *Dictyostelium*. *Cell* 1995;80:139–48.
- [26] Ryves WJ, Harwood AJ. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. *Biochem Biophys Res Commun* 2001;280:720–5.
- [27] Ryves WJ, Dajani R, Pearl L, Harwood AJ. Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. *Biochem Biophys Res Commun* 2002; 290:967–72.
- [28] Hallcher LM, Sherman WR. The effects of lithium ion and other agents on the activity of *myo*-inositol-1-phosphatase from bovine brain. *J Biol Chem* 1980;255:10896–901.
- [29] Mikoshiba K. Inositol 1,4,5-trisphosphate receptor. *Trends Pharmacol Sci* 1993;14:86–9.
- [30] Sasakawa N, Sharif M, Hanley MR. Metabolism and biological activities of inositol pentakisphosphate and inositol hexakisphosphate. *Biochem Pharmacol* 1995;50:137–46.
- [31] Czech MP. PIP2 and PIP3: complex roles at the cell surface. *Cell* 2000;100:603–6.
- [32] Berridge MJ. Inositol trisphosphate and diacylglycerol: two interacting second messengers. *Annu Rev Biochem* 1987;56:159–93.
- [33] Maeda T, Eisenberg Jr F. Purification, structure, and catalytic properties of *L-my*o-inositol-1-phosphate synthase from rat testis. *J Biol Chem* 1980;255:8458–64.
- [34] Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. *Cell* 1989;59:411–9.
- [35] Allison JH, Boshans RL, Hallcher LM, Packman PM, Sherman WR. The effects of lithium on *myo*-inositol levels in layers of frontal cerebral cortex, in cerebellum, and in corpus callosum of the rat. *J Neurochem* 1980;34:456–8.
- [36] Sherman WR, Leavitt AL, Honchar MP, Hallcher LM, Phillips BE. Evidence that lithium alters phosphoinositide metabolism: chronic administration elevates primarily *D-my*o-inositol-1-phosphate in cerebral cortex of the rat. *J Neurochem* 1981;36:1947–51.
- [37] Lee CH, Dixon JF, Reichman M, Moumni C, Los G, Hokin LE. Li⁺ increases accumulation of inositol 1,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate in cholinergically stimulated brain cortex slices in guinea pig, mouse and rat. The increases require inositol

- supplementation in mouse and rat but not in guinea pig. *Biochem J* 1992;282(Pt 2):377–85.
- [38] Dixon JF, Hokin LE. Lithium stimulates accumulation of second-messenger inositol 1,4,5-trisphosphate and other inositol phosphates in mouse pancreatic minilobules without inositol supplementation. *Biochem J* 1994;304(Pt 1):251–8.
- [39] Hokin LE, Dixon JF, Los GV. A novel action of lithium: stimulation of glutamate release and inositol 1,4,5 trisphosphate accumulation via activation of the *N*-methyl *D*-aspartate receptor in monkey and mouse cerebral cortex slices. *Adv Enzyme Regul* 1996;36:229–44.
- [40] Soares JC, Mann JJ. The functional neuroanatomy of mood disorders. *J Psychiatr Res* 1997;31:393–432.
- [41] Strakowski SM, DelBello MP, Adler C, Cecil DM, Sax KW. Neuroimaging in bipolar disorder. *Bipolar Disord* 2000;2:148–64.
- [42] Acharya JK, Labarca P, Delgado R, Jalink K, Zuker CS. Synaptic defects and compensatory regulation of inositol metabolism in inositol polyphosphate 1-phosphatase mutants. *Neuron* 1998;20:1219–29.
- [43] Williams RS, Cheng L, Mudge AW, Harwood AJ. A common mechanism of action for three mood-stabilizing drugs. *Nature* 2002;417:292–5.
- [44] Kofman O, Belmaker RH. Intracerebroventricular *myo*-inositol antagonizes lithium-induced suppression of rearing behaviour in rats. *Brain Res* 1990;534:345–7.
- [45] Kofman O, Belmaker RH, Grisaru N, Alpert C, Fuchs I, Katz V, Rigler O. *Myo*-inositol attenuates two specific behavioral effects of acute lithium in rats. *Psychopharmacol Bull* 1991;27:185–90.
- [46] Agam G, Shapiro Y, Bersudsky Y, Kofman O, Belmaker RH. High-dose peripheral inositol raises brain inositol levels and reverses behavioral effects of inositol depletion by lithium. *Pharmacol Biochem Behav* 1994;49:341–3.
- [47] Williams MB, Jope RS. Modulation by inositol of cholinergic- and serotonergic-induced seizures in lithium-treated rats. *Brain Res* 1995;685:169–78.
- [48] Belmaker RH, Bersudsky Y, Agam G, Levine J, Kofman O. How does lithium work on manic depression? Clinical and psychological correlates of the inositol theory. *Annu Rev Med* 1996;47:47–56.
- [49] Levine J, Barak Y, Kofman O, Belmaker RH. Follow-up and relapse analysis of an inositol study of depression. *Isr J Psychiatry Relat Sci* 1995;32:14–21.
- [50] Levine J, Barak Y, Gonzalves M, Szor H, Elizur A, Kofman O, Belmaker RH. Double-blind, controlled trial of inositol treatment of depression. *Am J Psychiatry* 1995;152:792–4.
- [51] Cohen P. The Croonian Lecture 1998. Identification of a protein kinase cascade of major importance in insulin signal transduction. *Philos Trans R Soc Lond B Biol Sci* 1999;354:485–95.
- [52] Rodriguez-Gil JE, Guinovart JJ, Bosch F. Lithium restores glycogen synthesis from glucose in hepatocytes from diabetic rats. *Arch Biochem Biophys* 1993;301:411–5.
- [53] Doble B, Woodgett J. GSK-3: tricks of the trade for a multi-tasking kinase. *J Cell Sci* 2003;116(Pt 7):1175–86.
- [54] Harwood AJ. Regulation of GSK-3: a cellular multiprocessor. *Cell* 2001;105:821–4.
- [55] Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. *Genes Dev* 1997;11:3286–305.
- [56] Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. *Annu Rev Cell Dev Biol* 1998;14:59–88.
- [57] Miller JR, Hocking AM, Brown JD, Moon RT. Mechanism and function of signal transduction by the Wnt/ β -catenin and Wnt/ Ca^{2+} pathways. *Oncogene* 1999;18:7860–72.
- [58] He X, Saint-Jeannet JP, Woodgett JR, Varmus HE, Dawid IB. Glycogen synthase kinase-3 and dorsoventral patterning in *Xenopus* embryos. *Nature* 1995;374:617–22.
- [59] Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics *Wingless* signaling in intact cells. *Curr Biol* 1996;6:1664–8.
- [60] Gavin BJ, McMahon JA, McMahon AP. Expression of multiple novel *Wnt-1/int-1*-related genes during fetal and adult mouse development. *Genes Dev* 1990;4:2319–32.
- [61] Hall AC, Lucas FR, Salinas PC. Axonal remodeling and synaptic differentiation in the cerebellum is regulated by WNT-7a signaling. *Cell* 2000;100:525–35.
- [62] Lucas FR, Salinas PC. WNT-7a induces axonal remodeling and increases synapsin I levels in cerebellar neurons. *Dev Biol* 1997;192:31–44.
- [63] Krylova O, Messenger MJ, Salinas PC. Dishevelled-1 regulates microtubule stability: a new function mediated by glycogen synthase kinase-3 β . *J Cell Biol* 2000;151:83–94.
- [64] Lucas FR, Goold RG, Gordon-Weeks PR, Salinas PC. Inhibition of GSK-3 β leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium. *J Cell Sci* 1998;111:1351–61.
- [65] Takei Y, Teng J, Harada A, Hirokawa N. Defects in axonal elongation and neuronal migration in mice with disrupted *tau* and *map1b* genes. *J Cell Biol* 2000;150:989–1000.
- [66] Jacobs BL. Adult brain neurogenesis and depression. *Brain Behav Immun* 2002;16:602–9.
- [67] Turlejski K, Djavadian R. Life-long stability of neurons: a century of research on neurogenesis, neuronal death and neuron quantification in adult CNS. *Prog Brain Res* 2002;136:39–65.
- [68] Gould E, McEwen BS, Tanapat P, Galea LA, Fuchs E. Neurogenesis in the dentate gyrus of the adult tree shrew is regulated by psychosocial stress and NMDA receptor activation. *J Neurosci* 1997;17:2492–8.
- [69] Gould E, Tanapat P, McEwen BS, Flugge G, Fuchs E. Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress. *Proc Natl Acad Sci USA* 1998;95:3168–71.
- [70] Kempermann G, Gage FH. Experience-dependent regulation of adult hippocampal neurogenesis: effects of long-term stimulation and stimulus withdrawal. *Hippocampus* 1999;9:321–32.
- [71] van Praag H, Kempermann G, Gage FH. Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus. *Nat Neurosci* 1999;2:266–70.
- [72] Kempermann G, van Praag H, Gage FH. Activity-dependent regulation of neuronal plasticity and self repair. *Prog Brain Res* 2000;127:35–48.
- [73] Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. Enhancement of hippocampal neurogenesis by lithium. *J Neurochem* 2000;75:1729–34.
- [74] Polakis P. Wnt signaling and cancer. *Genes Dev* 2000;14:1837–51.
- [75] He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of *c-MYC* as a target of the APC pathway. *Science* 1998;281:1509–12.
- [76] Tetsu O, McCormick F. β -Catenin regulates expression of cyclin D1 in colon carcinoma cells. *Nature* 1999;398:422–6.
- [77] Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A. The cyclin D1 gene is a target of the β -catenin/LEF-1 pathway. *Proc Natl Acad Sci USA* 1999;96:5522–7.
- [78] Kang DE, Soriano S, Frosch MP, Collins T, Naruse S, Sisodia SS, Leibowitz G, Levine F, Koo EH. Presenilin 1 facilitates the constitutive turnover of β -catenin: differential activity of Alzheimer's disease-linked PS1 mutants in the β -catenin-signaling pathway. *J Neurosci* 1999;19:4229–37.
- [79] Kang DE, Soriano S, Xia X, Eberhart CG, De Strooper B, Zheng H, Koo EH. Presenilin couples the paired phosphorylation of β -catenin independent of axin: implications for β -catenin activation in tumorigenesis. *Cell* 2002;110:751–62.
- [80] Xia X, Qian S, Soriano S, Wu Y, Fletcher AM, Wang XJ, Koo EH, Wu X, Zheng H. Loss of presenilin 1 is associated with enhanced β -catenin signaling and skin tumorigenesis. *Proc Natl Acad Sci USA* 2001;98:10863–8.

- [81] Jia J, Amanai K, Wang G, Tang J, Wang B, Jiang J. Shaggy/GSK3 antagonizes Hedgehog signalling by regulating *Cubitus interruptus*. *Nature* 2002;416:548–52.
- [82] Price MA, Kalderon D. Proteolysis of the Hedgehog signaling effector *Cubitus interruptus* requires phosphorylation by Glycogen Synthase Kinase 3 and Casein Kinase 1. *Cell* 2002;108:823–35.
- [83] Kenney AM, Rowitch DH. Sonic hedgehog promotes G₁ cyclin expression and sustained cell cycle progression in mammalian neuronal precursors. *Mol Cell Biol* 2000;20:9055–67.
- [84] Duman-Scheel M, Weng L, Xin S, Du W. Hedgehog regulates cell growth and proliferation by inducing cyclin D and cyclin E. *Nature* 2002;417:299–304.
- [85] Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3 β regulates cyclin D1 proteolysis and subcellular localization. *Genes Dev* 1998;12:3499–511.
- [86] Takashima A, Noguchi K, Sato K, Hoshino T, Imahori K. Tau protein kinase I is essential for amyloid β -protein-induced neurotoxicity. *Proc Natl Acad Sci USA* 1993;90:7789–93.
- [87] Takashima A, Noguchi K, Michel G, Mercken M, Hoshi M, Ishiguro K, Imahori K. Exposure of rat hippocampal neurons to amyloid β peptide (25–35) induces the inactivation of phosphatidylinositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 β . *Neurosci Lett* 1996;203:33–6.
- [88] Longo KA, Kennell JA, Ochocinska MJ, Ross SE, Wright WS, MacDougald OA. Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors. *J Biol Chem* 2002;277:38239–44.
- [89] Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. *J Biol Chem* 1998;273:19929–32.
- [90] Hetman M, Cavanaugh JE, Kimelman D, Xia Z. Role of glycogen synthase kinase-3 β in neuronal apoptosis induced by trophic withdrawal. *J Neurosci* 2000;20:2567–74.
- [91] Bijur GN, De Sarno P, Jope RS. Glycogen synthase kinase-3 β facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. *J Biol Chem* 2000;275:7583–90.
- [92] Bhat RV, Shanley J, Correll MP, Fieles WE, Keith RA, Scott CW, Lee CM. Regulation and localization of tyrosine²¹⁶ phosphorylation of glycogen synthase kinase-3 β in cellular and animal models of neuronal degeneration. *Proc Natl Acad Sci USA* 2000;97:11074–9.
- [93] Lucas JJ, Hernández F, Gómez-Ramos P, Morán MA, Hen R, Avila J. Decreased nuclear β -catenin, tau hyperphosphorylation and neurodegeneration in GSK-3 β conditional transgenic mice. *EMBO J* 2001;20:27–39.
- [94] Bijur GN, Jope RS. Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 β . *J Biol Chem* 2001;276:37436–42.
- [95] King TD, Bijur GN, Jope RS. Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3 β and attenuated by lithium. *Brain Res* 2001;919:106–14.
- [96] Lu R, Song L, Jope RS. Lithium attenuates p53 levels in human neuroblastoma SH-SY5Y cells. *Neuroreport* 1999;10:1123–5.
- [97] Jope RS, Bijur GN. Mood stabilizers, glycogen synthase kinase-3 β and cell survival. *Mol Psychiatry* 2002;7(Suppl. 1):S35–45.
- [98] Chen RW, Chuang DM. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. *J Biol Chem* 1999;274:6039–42.
- [99] Farber NB, Jiang XP, Heinkel C, Nemmers B. Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. *Mol Psychiatry* 2002;7:726–33.
- [100] Chen G, Masana MI, Manji HK. Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS *in vivo*. *Bipolar Disord* 2000;2:217–36.
- [101] Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH, Manji HK. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. *J Neurochem* 1999;72:879–82.
- [102] Chen G, Yuan PX, Jiang YM, Huang LD, Manji HK. Valproate robustly enhances AP-1 mediated gene expression. *Brain Res Mol Brain Res* 1999;64:52–8.
- [103] Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. *J Biol Chem* 2001;276:31674–83.
- [104] Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. *CNS Drugs* 2002;16:695–714.
- [105] Chen G, Huang LD, Jiang YM, Manji HK. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. *J Neurochem* 1999;72:1327–30.
- [106] Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. *J Biol Chem* 2001;276:36734–41.
- [107] Hall AC, Brennan A, Goold RG, Cleverley K, Lucas FR, Gordon-Weeks PR, Salinas PC. Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. *Mol Cell Neurosci* 2002;20:257–70.
- [108] Lemperiere T. [Brief history of the development of valproate in bipolar disorders]. *Encephale* 2001;27:365–72.
- [109] Lemoine P, Fondarai J, Faivre T. Valpromide increases amplitude of heart rate circadian rhythm in remitted bipolar and unipolar disorders. A placebo-controlled study. *Eur Psychiatry* 2000;15:424–32.
- [110] Vaden DL, Ding D, Peterson B, Greenberg ML. Lithium and valproate decrease inositol mass and increase expression of the yeast *INO1* and *INO2* genes for inositol biosynthesis. *J Biol Chem* 2001;276:15466–71.
- [111] O'Donnell T, Rotzinger S, Nakashima TT, Hanstock CC, Ulrich M, Silverstone PH. Chronic lithium and sodium valproate both decrease the concentration of *myo*-inositol and increase the concentration of inositol monophosphates in rat brain. *Brain Res* 2000;880:84–91.
- [112] Silverstone PH, Wu RH, O'Donnell T, Ulrich M, Asghar SJ, Hanstock CC. Chronic treatment with both lithium and sodium valproate may normalize phosphoinositol cycle activity in bipolar patients. *Hum Psychopharmacol* 2002;17:321–7.
- [113] Emilien G, Maloteaux JM, Seghers A, Charles G. Lithium therapy in the treatment of manic-depressive illness. Present status and future perspectives. A critical review. *Arch Int Pharmacodyn Ther* 1995;330:251–78.
- [114] Li X, Bijur GN, Jope RS. Glycogen synthase kinase-3 β , mood stabilizers, and neuroprotection. *Bipolar Disord* 2002;4:137–44.
- [115] Dubovsky SL, Thomas M, Hijazi A, Murphy J. Intracellular calcium signalling in peripheral cells of patients with bipolar affective disorder. *Eur Arch Psychiatry Clin Neurosci* 1994;243:229–34.
- [116] Harwood AJ. Signal transduction and Dictyostelium development. *Protist* 2001;152:17–29.
- [117] Williams RS, Eames M, Ryves WJ, Viggars J, Harwood AJ. Loss of a prolyl oligopeptidase confers resistance to lithium by elevation of inositol (1,4,5) trisphosphate. *EMBO J* 1999;18:2734–45.
- [118] Van Dijken P, de Haas JR, Craxton A, Erneux C, Shears SB, Van Haastert PJM. A novel, phospholipase C-independent pathway of inositol 1,4,5-trisphosphate formation in *Dictyostelium* and rat liver. *J Biol Chem* 1995;270:29724–31.
- [119] Polgar L. The prolyl oligopeptidase family. *Cell Mol Life Sci* 2002;59:349–62.
- [120] Morain P, Lestage P, De Nanteuil G, Jochemsen R, Robin JL, Guez D, Boyer PA. S 17092: a prolyl endopeptidase inhibitor as a potential therapeutic drug for memory impairment. Preclinical and clinical studies. *CNS Drug Rev* 2002;8:31–52.
- [121] Shinoda M, Miyazaki A, Toide K. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on spatial memory and on cholinergic

- and peptidergic neurons in rats with ibotenate-induced lesions of the nucleus basalis magnocellularis. *Behav Brain Res* 1999;99:17–25.
- [122] Toide K, Iwamoto Y, Fujiwara T, Abe H. JTP-4819: a novel prolyl endopeptidase inhibitor with potential as a cognitive enhancer. *J Pharmacol Exp Ther* 1995;274:1370–8.
- [123] Shishido Y, Furushiro M, Tanabe S, Nishiyama S, Hashimoto S, Ohno M, Yamamoto T, Watanabe S. ZTTA, a postproline cleaving enzyme inhibitor, improves cerebral ischemia-induced deficits in a three-panel runway task in rats. *Pharmacol Biochem Behav* 1996;55:333–8.
- [124] Calabrese JR, Woysville MJ. Lithium therapy: limitations and alternatives in the treatment of bipolar disorders. *Ann Clin Psychiatry* 1995;7:103–12.
- [125] Schulz I, Gerhartz B, Neubauer A, Holloschi A, Heiser U, Hafner M, Demuth HU. Modulation of inositol 1,4,5-triphosphate concentration by prolyl endopeptidase inhibition. *Eur J Biochem* 2002;269:5813–20.
- [126] Maes M, Goossens F, Scharpe S, Meltzer HY, D'Hondt P, Cosyns P. Lower serum prolyl endopeptidase enzyme activity in major depression: further evidence that peptidases play a role in the pathophysiology of depression. *Biol Psychiatry* 1994;35:545–52.
- [127] Maes M, Goossens F, Scharpe S, Calabrese J, Desnyder R, Meltzer HY. Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs. *Psychiatry Res* 1995;58:217–25.
- [128] Shimon H, Agam G, Belmaker RH, Hyde TM, Kleinman JE. Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. *Am J Psychiatry* 1997;154:1148–50.
- [129] Davanzo P, Thomas MA, Yue K, Oshiro T, Belin T, Strober M, McCracken J. Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder. *Neuropsychopharmacology* 2001;24:359–69.
- [130] Shapiro J, Belmaker RH, Biegon A, Seker A, Agam G. Scyllo-inositol in post-mortem brain of bipolar, unipolar and schizophrenic patients. *J Neural Transm* 2000;107:603–7.
- [131] Belmaker RH, Shapiro J, Vainer E, Nemanov L, Ebstein RP, Agam G. Reduced inositol content in lymphocyte-derived cell lines from bipolar patients. *Bipolar Disord* 2002;4:67–9.
- [132] Banks RE, Aiton JF, Cramb G, Naylor GJ. Incorporation of inositol into the phosphoinositides of lymphoblastoid cell lines established from bipolar manic-depressive patients. *J Affect Disord* 1990;19:1–8.
- [133] Soares JC, Mallinger AG, Dippold CS, Forster Wells K, Frank E, Kupfer DJ. Effects of lithium on platelet membrane phosphoinositides in bipolar disorder patients: a pilot study. *Psychopharmacology (Berl)* 2000;149:12–6.
- [134] Shamir A, Ebstein RP, Nemanov L, Zohar A, Belmaker RH, Agam G. Inositol monophosphatase in immortalized lymphoblastoid cell lines indicates susceptibility to bipolar disorder and response to lithium therapy. *Mol Psychiatry* 1998;3:481–2.
- [135] Shaltiel G, Nemanov L, Yaroslavsky Y, Nemets B, Ebstein RP, Belmaker RH, Agam G. Inositol monophosphatase activity in brain and lymphocyte-derived cell lines of bipolar, schizophrenic and unipolar patients. *World J Biol Psychiatry* 2001;2:93–6.
- [136] Nemanov L, Ebstein RP, Belmaker RH, Osher Y, Agam G. Effect of bipolar disorder on lymphocyte inositol monophosphatase mRNA levels. *Int J Neuropsychopharmacol* 1999;2:25–9.
- [137] Lubrich B, Spleiss O, Gebicke-Haerter PJ, van Calker D. Differential expression, activity and regulation of the sodium/myo-inositol cotransporter in astrocyte cultures from different regions of the rat brain. *Neuropharmacology* 2000;39:680–90.
- [138] Lubrich B, van Calker D. Inhibition of the high affinity myo-inositol transport system: a common mechanism of action of antibipolar drugs? *Neuropsychopharmacology* 1999;21:519–29.
- [139] Wolfson M, Bersudsky Y, Zinger E, Simkin M, Belmaker RH, Hertz L. Chronic treatment of human astrocytoma cells with lithium, carbamazepine or valproic acid decreases inositol uptake at high inositol concentrations but increases it at low inositol concentrations. *Brain Res* 2000;855:158–61.
- [140] Wolfson M, Hertz E, Belmaker RH, Hertz L. Chronic treatment with lithium and pretreatment with excess inositol reduce inositol pool size in astrocytes by different mechanisms. *Brain Res* 1998;787:34–40.
- [141] van Calker D, Belmaker RH. The high affinity inositol transport system—implications for the pathophysiology and treatment of bipolar disorder. *Bipolar Disord* 2000;2:102–7.